KalVista Pharmaceuticals : Submission of Matters to a Vote of Security Holders (Form 8-K)
October 04, 2021 at 08:08 am EDT
Share
Submission of Matters to a Vote of Security Holders.
On September 30, 2021, KalVista Pharmaceuticals, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders ("Annual Meeting") and the following proposals were adopted:
1.
Election of three Class III directors, Albert Cha, Martin Edwards and Nancy Stuart (each to serve a three-year term, which will expire at the 2024 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified):
Nominees
Shares For
Shares Against
Shares Abstaining
Broker Non-Votes
Albert Cha
16,672,347
5,474,494,
215
464,900
Martin Edwards
13,508,127
8,638,709
220
464,900
Nancy Stuart
21,393,389
753,360
307
464,900
2.
Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2022:
Shares For
Shares Against
Shares Abstaining
Broker Non-Votes
22,598,162
13,627
167
0
3.
Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers:
Shares For
Shares Against
Shares Abstaining
Broker Non-Votes
19,696,080
2,450,450
526
464,900
Attachments
Original document
Permalink
Disclaimer
Kalvista Pharmaceuticals Inc. published this content on 04 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2021 12:01:38 UTC.
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.
KALVISTA PHARMACEUTICALS, INC. 
